Phase II/III trial demonstrates sustained 52-week efficacy and safety of ozoralizumab in methotrexate-resistant rheumatoid arthritis, suggesting a durable targeted treatment option.
Ozoralizumab demonstrated significant therapeutic effects and efficacy, which was maintained for 52 weeks. The safety profile was consistent with the evaluated results in interim analysis at Week 24, and ozoralizumab was well-tolerated up to Week 52.
No takes yet. Share an insight, caveat, or question.
Tanaka et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: